Leading on Biosimilars: 2017 AAM Biosimilars Council Conference Preview
Join us as we examine the promise of biosimilars in the United States and discuss how best to ensure patient access to these treatments. Seats at our two-day conference are limited, so reserve your spot now for Leading on Biosimilars.
The first day of the #LeadingOnBiosimilars conference will feature a talk from Adrian van den Hoven, the Director General of Medicines for Europe. This will be a unique opportunity to gain insight into the European experience regarding biosimilars and lessons U.S biosimilars market stakeholders can use to maximize access for patients. Conference attendees will have the opportunity to hear about the opportunities expanded biosimilars availability provides, not only for a robust market and continued innovation but also for patient access. As Director General, Adrian and his team represent the pharmaceutical companies supplying the largest share of biosimilars medicines across Europe and are the voice of the biosimilars industry in Europe.
Market Access, Market Promise
Day 1 of the conference will also feature a panel entitled “Market Access, Market Promise” moderated by Elizabeth Jex, Attorney Advisor in the Office of Policy Planning at the Federal Trade Commission (FTC). The panel will discuss barriers biosimilars manufacturers face when trying to enter the U.S. market, including anti-competitive tactics used by brand manufacturers and how the federal government and biosimilars industry are dealing with these issues.
The Promise of Biosimilars:
How Patient Advocates Are Educating on the Role of Biosimilars in Patient Care
A key focus of this conference will be sessions dedicated to educating the public, patients and healthcare professionals about the safety and effectiveness of biosimilars. The last panel of the first day will include patient advocates from the Crohn’s & Colitis Foundation, CancerCare, the Black Women’s Health Imperative and the Cancer Support Community and how their organizations educate their constituencies and networks on the potential of biosimilars. The panel will talk about lessons learned from outreach efforts and give their perspective on how to best inform patients and families about the promise of biosimilars.
We look forward to seeing you September 12-13. Connect with us on social media and let us know which panel you are most looking forward to attending:
Seats at the 2017 Conference are limited, reserve your space here.
Visit the Facebook event page here.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at www.accesiblemeds.org.